Changing the Subject: The “All-Cancer Trial”
Executive Summary
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. One idea: a nationwide clinical trial open to every patient with a cancer diagnosis.
You may also be interested in...
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.